XML 270 R213.htm IDEA: XBRL DOCUMENT v3.25.0.1
Disclosures about major customers and credit risk (Details) - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of information about major customers and credit risk [line items]      
Percentage of entity's revenue (in percent)     8.00%
Net sales € 41,081 € 37,817 [1] € 37,651 [1]
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 41,081 37,817 [1] 37,651 [1]
Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 41,081 37,817 [2],[3] 37,651 [3],[4],[5]
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 41,081 37,817 [2],[3] 37,651 [3],[4],[5]
Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 1,316 1,266 [3] 1,309 [3]
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 1,316 1,266 [3] 1,309 [3]
Launches | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 4,535 2,237 [3] 951 [3]
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales € 4,535 € 2,237 [3] € 951 [3]
Largest customers      
Disclosure of information about major customers and credit risk [line items]      
Percentage of entity's revenue (in percent) 34.00%    
Customer one      
Disclosure of information about major customers and credit risk [line items]      
Percentage of entity's revenue (in percent) 15.00% 13.00% 13.00%
Customer two      
Disclosure of information about major customers and credit risk [line items]      
Percentage of entity's revenue (in percent) 11.00% 10.00% 9.00%
Customer three      
Disclosure of information about major customers and credit risk [line items]      
Percentage of entity's revenue (in percent) 8.00% 8.00%  
Europe      
Disclosure of information about major customers and credit risk [line items]      
Net sales € 9,027 € 8,816 [6] € 8,490 [7]
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 9,027 8,816 [6] 8,490 [7]
Europe | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 9,027 8,816 8,490
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 9,027 8,816 8,490
Europe | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 204 157 112
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 204 157 112
Europe | Launches | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 960 491 215
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 960 491 215
US      
Disclosure of information about major customers and credit risk [line items]      
Net sales 19,986 17,262 [6] 16,986 [7]
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 19,986 17,262 [6] 16,986 [7]
US | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 19,986 17,262 16,986
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 19,986 17,262 16,986
US | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 736 730 767
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 736 730 767
US | Launches | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 2,998 1,533 623
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 2,998 1,533 623
Other Countries In Segment Results [Member] | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 12,068 11,739 12,175
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 12,068 11,739 12,175
Other Countries In Segment Results [Member] | Meningitis, Travel And Endemics Vaccines | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 376 379 430
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales 376 379 430
Other Countries In Segment Results [Member] | Launches | Biopharma (operating segment)      
Disclosure of information about major customers and credit risk [line items]      
Net sales 577 213 113
Disclosure of disaggregation of revenue from contracts with customers [line items]      
Net sales € 577 € 213 € 113
[1] Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation
[2] Figures for the comparative period (2023) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[3] (a)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[4] (a) Figures for the comparative period (2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[5] (b) 2022 business operating income has been recast from the amount previously reported to include the one-time income of €952 million from the Libtayo
transaction (€706 million net of tax).
[6] (a)Figures for 2023 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.
[7] (a)Figures for 2022 have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued operation.